Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACTU: FMT vs Mesalazine in Active Left-Sided Ulcerative Colitis
NCT03104036Phase 2Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jun 2017
- Primary completion
- Jan 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in ulcerative colitis (UC), sponsored by Institute for Clinical and Experimental Medicine. Started Jun 2017; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03104036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104036.